- Home
- ACAD vs DOCN Comparison
ACAD vs DOCN Comparison
Compare ACAD & DOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- DOCN
- Stock Information
- Founded
- ACAD 1993
- DOCN 2011
- Country
- ACAD United States
- DOCN United States
- Employees
- ACAD N/A
- DOCN 1210
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- DOCN Retail: Computer Software & Peripheral Equipment
- Sector
- ACAD Health Care
- DOCN Technology
- Exchange
- ACAD Nasdaq
- DOCN Nasdaq
- Market Cap
- ACAD 2.8B
- DOCN 2.5B
- IPO Year
- ACAD 2004
- DOCN 2021
- Fundamental
- Price
- ACAD $14.73
- DOCN $27.38
- Analyst Decision
- ACAD Buy
- DOCN Buy
- Analyst Count
- ACAD 16
- DOCN 13
- Target Price
- ACAD $23.93
- DOCN $42.83
- AVG Volume (30 Days)
- ACAD 1.8M
- DOCN 1.5M
- Earning Date
- ACAD 05-07-2025
- DOCN 05-06-2025
- Dividend Yield
- ACAD N/A
- DOCN N/A
- EPS Growth
- ACAD N/A
- DOCN 345.00
- EPS
- ACAD 1.36
- DOCN 0.89
- Revenue
- ACAD $957,797,000.00
- DOCN $780,615,000.00
- Revenue This Year
- ACAD $13.07
- DOCN $15.43
- Revenue Next Year
- ACAD $9.88
- DOCN $13.98
- P/E Ratio
- ACAD $10.83
- DOCN $30.76
- Revenue Growth
- ACAD 31.85
- DOCN 12.66
- 52 Week Low
- ACAD $13.40
- DOCN $25.45
- 52 Week High
- ACAD $20.68
- DOCN $47.02
- Technical
- Relative Strength Index (RSI)
- ACAD 38.07
- DOCN 35.04
- Support Level
- ACAD $14.34
- DOCN $26.91
- Resistance Level
- ACAD $15.18
- DOCN $28.69
- Average True Range (ATR)
- ACAD 0.80
- DOCN 2.60
- MACD
- ACAD -0.02
- DOCN -0.15
- Stochastic Oscillator
- ACAD 38.22
- DOCN 19.48
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About DOCN DigitalOcean Holdings Inc.
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.